These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany. Wirth D; Dass R; Hettle R BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207 [TBL] [Abstract][Full Text] [Related]
45. Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed Drugs. Lotia Farrukh I; Lachenal N; Adenov MM; Ahmed S; Algozhin Y; Coutisson S; Garavito ES; Hewison C; Holtzman D; Huerga H; Janmohamed A; Khan PY; Jacques GL; Lomtadze N; Melikyan N; Mitnick CD; Mussabekova G; Osso E; Perea S; Putri FA; Rashidov M; Rich ML; Sakhabutdinova Y; Seung KJ; Stambekova A; Vásquez DV; Franke MF; Khan U Clin Infect Dis; 2024 Jan; 78(1):144-148. PubMed ID: 37606512 [TBL] [Abstract][Full Text] [Related]
46. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Pym AS; Diacon AH; Tang SJ; Conradie F; Danilovits M; Chuchottaworn C; Vasilyeva I; Andries K; Bakare N; De Marez T; Haxaire-Theeuwes M; Lounis N; Meyvisch P; Van Baelen B; van Heeswijk RP; Dannemann B; Eur Respir J; 2016 Feb; 47(2):564-74. PubMed ID: 26647431 [TBL] [Abstract][Full Text] [Related]
47. Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls. Kakkar AK; Dahiya N Tuberculosis (Edinb); 2014 Jul; 94(4):357-62. PubMed ID: 24841672 [TBL] [Abstract][Full Text] [Related]
48. Performance of the GenoType MTBDRsl assay for the detection second-line anti-tuberculosis drug resistance. Lee YS; Lee BY; Jo KW; Shim TS J Infect Chemother; 2017 Dec; 23(12):820-825. PubMed ID: 29066216 [TBL] [Abstract][Full Text] [Related]
49. Shorter & cheaper regimen to treat multidrug-resistant tuberculosis: A new hope. Prasad R; Gupta N; Banka A Indian J Med Res; 2017 Sep; 146(3):301-303. PubMed ID: 29355135 [No Abstract] [Full Text] [Related]
50. Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis. Kunkel A; Cobelens FG; Cohen T PLoS Med; 2016 Oct; 13(10):e1002142. PubMed ID: 27727274 [TBL] [Abstract][Full Text] [Related]
51. New World Health Organization Treatment Recommendations for Multidrug-Resistant Tuberculosis: Are We Well Enough Prepared? Kranzer K; Kalsdorf B; Heyckendorf J; Andres S; Merker M; Hofmann-Thiel S; Bloemberg GV; Hoffmann H; Niemann S; Lange C; Maurer FP Am J Respir Crit Care Med; 2019 Aug; 200(4):514-515. PubMed ID: 31026398 [No Abstract] [Full Text] [Related]
52. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis. Chahine EB; Karaoui LR; Mansour H Ann Pharmacother; 2014 Jan; 48(1):107-15. PubMed ID: 24259600 [TBL] [Abstract][Full Text] [Related]
53. Minimising the threat of bedaquiline-resistant tuberculosis: better diagnosis as prevention. Zemanay W; Cox H Lancet Infect Dis; 2024 Mar; 24(3):226-228. PubMed ID: 37956678 [No Abstract] [Full Text] [Related]
54. Novel drugs against tuberculosis: a clinician's perspective. Olaru ID; von Groote-Bidlingmaier F; Heyckendorf J; Yew WW; Lange C; Chang KC Eur Respir J; 2015 Apr; 45(4):1119-31. PubMed ID: 25431273 [TBL] [Abstract][Full Text] [Related]
55. New drug targets resistant tuberculosis. Wilkinson A CMAJ; 2013 Oct; 185(15):E699-700. PubMed ID: 24016791 [No Abstract] [Full Text] [Related]
56. Reply to comments by Kakkar and Dahiya. Chahine EB; Karaoui L; Mansour H Ann Pharmacother; 2014 May; 48(5):667. PubMed ID: 24733170 [No Abstract] [Full Text] [Related]
57. Bedaquiline (Sirturo) for multidrug-resistant tuberculosis. Med Lett Drugs Ther; 2013 Aug; 55(1423):66-8. PubMed ID: 23959388 [No Abstract] [Full Text] [Related]
58. Bedaquiline versus placebo for management of multiple drug-resistant tuberculosis: A systematic review. Charan J; Reljic T; Kumar A Indian J Pharmacol; 2016; 48(2):186-91. PubMed ID: 27127322 [TBL] [Abstract][Full Text] [Related]